Werner Lanthaler, Evotec CEO

Boehringer In­gel­heim, Evotec band with di­ag­nos­tics play­er to tack­le 'su­per­bugs' through joint ven­ture

Hav­ing of­fered fi­nan­cial sup­port to com­pa­nies de­vel­op­ing an­tibi­otics and fight­ing an­timi­cro­bial re­sis­tance, Boehringer In­gel­heim is launch­ing its own.

The Ger­man phar­ma is team­ing up with Evotec — the drug dis­cov­ery and de­vel­op­ment play­er with whom it al­ready has a long-run­ning R&D al­liance in oth­er ar­eas — and French di­ag­nos­tic com­pa­ny bio­Mérieux to start a joint ven­ture that will cre­ate both next-gen an­timi­cro­bials and di­ag­nos­tics to tack­le in­fec­tious dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.